HPV legislation in Nebraska

From SourceWatch
Jump to: navigation, search

Women in Government Ratings

Women in Government, a non-profit network of state level women legislators, receives significant funding from the pharmaceutical industry, including Merck, GlaxoSmithKline, and Digene Corporation -- all with products related to HPV vaccination and testing. According to their report, "The 'State' of Cervical Cancer Prevention in America - 2008" [1]:


POPULATION: 1,768,331


Incidence & Mortality (2008 Score / 2007 Score)

  • Cervical Cancer Incidence Rate: 7.6/100,000 (1/ 1)
  • Cervical Cancer Incidence Rate/Race: White: 7.3, Black: 8.7
  • Cervical Cancer Mortality Rate: 2.4/100,000 (1 / 1)
  • Cervical Cancer Mortality Rate/Race: White: 2.3


Screening (2008 Score / 2007 Score)

  • Cervical Cancer Screening Rate: 81.6% (1 / 2)
  • Cervical Cancer Screening Rate/Race: White: 81.5%, Hispanic: 78.4%
  • % Uninsured/Unscreened: 20.4% (2 / 2)
  • Medicaid Coverage HPV Testing: Unrestricted (2 / 2)


Healthcare Access (2008 Score / 2007 Score)

  • Rate Uninsured Women: 15% (1 / 1)
  • % Low Income/Uninsured Women: 33%


Policy Initiatives and Infrastructure (2008 Score / Cumulative Score (2005–2008)

Screening Requirements (0 / 0)

  • There are no new screening requirements.

Task Forces (0 / 0)

  • There is no new cervical cancer prevention task force legislation.

Access to HPV Vaccines (0 / 0)

  • There is no HPV vaccine activity.

HPV Vaccine Information Programs (0 / 0)

  • There is no HPV vaccine information activity.

Miscellaneous (1 / 1)

  • LR 170 designates the Health and Human Services Committee to conduct an interim study of the Gardasil vaccine, including an examination of other states’ activities relative to use of the vaccine, on what populations it is used, and how it is funded; to Health and Human Services Committee.


Annual Ratings

  • 2008: Fair (9 out of 22 points)
  • 2007: Good (9 out of 18 points)


Articles and resources

SourceWatch Resources

External links

References